AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study
(Reuters) -AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare condition that causes a buildup of protein deposits in the body, the drugmaker said on Wednesday, sending shares down 1.3%.
The study was assessing a combination of how often patients with advanced, heart-related AL amyloidosis were hospitalised for cardiovascular issues, and death from any cause over a period of time, when compared with placebo.
While anselamimab did not achieve statistical significance for the overall population in the study, the therapy showed clinically meaningful improvement in a sub-group of patients, AstraZeneca said, without giving details of that group.
JPMorgan analyst James Gordon said that he expects the study "failure in all comers to be seen as a minor negative," adding that while AstraZeneca did not give details of the subgroup in which anselamimab worked, he believes the drugmaker may pursue regulatory approval there.
AL amyloidosis, also referred to as light chain or primary amyloidosis, leads to deposits of amyloid protein in the body because of defective plasma cells, and diagnosis is often delayed.
All patients in the AstraZeneca study had received standard of care for the plasma defect, and anselamimab or a placebo was given on top of that.
If left untreated, the accumulation of the deposits, particularly in the heart and kidneys, can progressively impair the quality of life causing organ damage and dysfunction, and lead to heart failure.
"Anselamimab is the first and only investigational fibril depleter to show clinical benefit in AL amyloidosis, and these results underscore its potential to address a critical treatment gap in a prespecified subgroup of patients," said Marc Dunoyer, CEO of AstraZeneca's rare diseases unit, Alexion, which is developing the treatment.
Anselamimab is a type of monoclonal antibody that binds itself to specific targets in the amyloid deposits and helps break them down. The company has forecast peak sales potential of $1 billion to $3 billion for the therapy, against overall annual sales of upwards of $50 billion.
AstraZeneca said it was evaluating the complete data on anselamimab, adding that it plans to share data with health authorities.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Darlington postie hopes to 'make a difference' with 400 mile walk to Cornwall
A Darlington postie on a mission to raise suicide awareness set off on a 400-mile trip to Cornwall today. Nikki Gaynor is no stranger to being on her feet all day, delivering parcels and letters on her postal route, but today (August 11), she began her "biggest challenge yet". Aiming to raise awareness for Chester-le-Street charity If U Care Share, Nikki, 50, will walk for 12 hours a day over two weeks to reach Launceston. Nikki Gaynor. (Image: STUART BOULTON) Spurred on by the loss of her friend to suicide, the gran will stop at Royal Mail offices on her route to deliver talks, hand out resources, and spread awareness. Nikki set off from the delivery office on St Cuthbert's Way, in a personalised green t-shirt, flanked by friends and supporters who cheered her on. Nikki previously told The Northern Echo: "Along the way, we're going to be handing out If U Care Share inside out packs - because it's suicide prevention day in September. Nikki Gaynor begins her 400 mile walk. (Image: STUART BOULTON) "We're trying to start a conversation about getting what's inside, out, and talk about mental health and suicide prevention as well." This is not the first mammoth effort Nikki has taken on. In 2024, she ran 5k every day, and this year she's hoping to walk 30 million steps. "Being a postie has made me excellent at it. I just really want to make a difference. If I can save one person, I've made a difference," she added. Nikki Gaynor begins her 400 mile walk. (Image: STUART BOULTON) She added: "I'm doing this because I lost a friend to suicide. The If U Care Share foundation helped me through the loss of them, and they were amazing with me. "I wanted to give back, so I've been fundraising for them since 2021. They have saved more than 4,000 people and are so needed in the area. "I want to keep shouting for them and make everyone aware that they are there if you need help." Nikki Gaynor is applauded by the fire service as she sets off. (Image: STUART BOULTON) Read more: Police search for missing Alex who failed to return home this week Darlington man 'Chop Off' strangled mother leaving her fearing for her life County Durham priest enlists TV's Dec to give parish announcement The picture postcard 'chocolate box' village under 2 hours from County Durham- Samaritans is available, day or night, 365 days of the year. You can call them for free on 116 123, email them at jo@ or visit to find your nearest branch. - If U Care Share on 0191 387 5661 or text IUCS to 85258 - SANE on 07984 967 708, Calm on 0800 58 58 58
The Verge
12 minutes ago
- The Verge
What's the point of a plastics treaty?
Posted Aug 11, 2025 at 7:27 PM UTC Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates. Justine Calma Posts from this author will be added to your daily email digest and your homepage feed. See All by Justine Calma Posts from this topic will be added to your daily email digest and your homepage feed. See All Climate Posts from this topic will be added to your daily email digest and your homepage feed. See All Environment Posts from this topic will be added to your daily email digest and your homepage feed. See All News Posts from this topic will be added to your daily email digest and your homepage feed. See All Policy Posts from this topic will be added to your daily email digest and your homepage feed. See All Science
Medscape
an hour ago
- Medscape
Coronary Sinus Reducer Shows Promise, With Caveats
The coronary sinus reducer, an hourglass-shaped stent that narrows the coronary sinus to increase coronary sinus pressure, has shown some promise in treating patients with refractory angina. But a meta-analysis published today in JACC: Cardiovascular Interventions found the benefits of the intervention are likely smaller than those early studies predicted. 'There have been lots of unblinded single-arm studies [of the procedure] but only three randomized controlled trials, so we wanted to look at the different effect sizes to better understand the overall potential efficacy,' said Rasha Al-Lamee, MD, a cardiologist at the National Heart and Lung Institute, part of Imperial College London, London, England, who led the meta-analysis. Al-Lamee and her colleagues looked at data from a combined total of 180 patients in the three trials, as well as 13 single-arm studies with 668 total patients. They found the coronary sinus procedure to be safe, with a success rate of 98.3%. But while both the single-arm and the controlled trials demonstrated improvements in symptoms of angina, the effect size was much smaller in the controlled trials. In the more rigorous trials, 26% of patients experienced at least a one-class improvement and 17% had at least a two-class improvement on the Canadian Cardiovascular Society classification of angina. Those figures were about one third of the gains reported in the single-arm trials. What's more, the randomized controlled trials found no evidence of benefit based on continuous measurements such as the Seattle Angina Questionnaire. Nor did they find improvements in objective measures such as myocardial perfusion associated with the intervention. Deepak Bhatt, MD, a cardiologist at the Icahn School of Medicine at Mount Sinai in New York City, who co-wrote an editorial accompanying the journal article, said more treatment options are needed for patients with refractory angina, who have often exhausted all other medical therapies and surgical procedures. But while coronary sinus reduction shows promise, the meta-analysis demonstrates why more, and larger, trials will be needed before clinicians can use it more broadly. 'It's not an inexpensive procedure, so we want substantial, objectively quantified evidence that it helps patients,' he told Medscape Medical News . 'History is littered with examples of things we were convinced worked but really didn't.' Percutaneous laser therapy, for example, seemed to show benefits for refractory angina at first, but more rigorous randomized trials found no benefit from the procedure, he said. The coronary sinus reducer device is already approved in the UK and Europe and its use is on the rise there, said Al-Lamee, but it has not yet been approved in the US. The ongoing COSIRA-II trial, with an estimated enrollment of 380 patients, should be well-powered enough to provide definitive results and support US approval, she said. Should COSIRA-II show definite benefit, she added, the device may become more of a frontline treatment, used before riskier revascularization options. 'Why have a redo of coronary artery bypass surgery if you have a device that is safe and effective?' she said. Al-Lamee had received consulting and speaker fees from Shockwave Medical, which makes the CSR device. Bhatt reported no relevant financial conflicts.
